Cancer and contraception

Contraception

Volumn 86, Issue 3, 2012, Pages 191-198

  Patel, Ashlesha ^a   Schwarz, E Bimla ^a  

^a NONE

Author keywords

Cancer; Contraception

Indexed keywords

COPPER INTRAUTERINE DEVICE; ESTROGEN; GESTAGEN; LEVONORGESTREL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CONTRACEPTIVE AGENT;

ANEMIA; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVOR; CONTRACEPTION; ENDOMETRIUM; FAMILY PLANNING; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL INFORMATION; MEDICAL LITERATURE; NEOPLASM; OSTEOPENIA; OSTEOPOROSIS; PATIENT SAFETY; PRACTICE GUIDELINE; PREGNANCY; THERAPY EFFECT; VENOUS THROMBOEMBOLISM; BREAST TUMOR; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; METHODOLOGY;

ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; ESTROGENS; FEMALE; HUMANS; IMMUNOSUPPRESSION; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; NEOPLASMS; OSTEOPOROSIS; PROGESTINS; TAMOXIFEN; VENOUS THROMBOEMBOLISM;

EID: 84865102284     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.05.008     Document Type: Article

References (111)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300 Epub 2010/07/09 (Evidence Grade: II-2)
2. S.F. Altekruse, C.L. Kosary, M. Krapcho, SEER cancer statistics review, 1975-2007 2010 National Cancer Institute Bethesda, MD http://seer.cancer.gov/ csr/1975-2007/ based on November 2009 SEER data submission, posted to the SEER web site. (Evidence Grade: II-2)
3. (US) NIH Surveillance epidemiology and end results. Bethesda, MD 2010 [cited 2011 June 10]; Available from: http://seer.cancer.gov/faststats/ selections.php?#Output (Evidence Grade: II-2)
4. A. Hordern Intimacy and sexuality after cancer: a critical review of the literature Cancer Nurs 31 2 2008 E9 E17 Epub 2008/05/21 (Evidence Grade: III)
5. A.J. Hordern, and A.F. Street Let's talk about sex: risky business for cancer and palliative care clinicians Contemp Nurse 27 2007 49 60 Epub 2008/04/05 (Evidence Grade: III)
6. M.F. Mitwally Management of reproductive needs in cancer patients: clinical perspectives Expert Rev Anticancer Ther 8 2008 1589 1595 (Evidence Grade: III)
7. V. Laurence, B.A. Gbolade, S.J. Morgan, and A. Glaser Contraception for teenagers and young adults with cancer Eur J Cancer 40 2004 2705 2716 Epub 2004/12/02 (Evidence Grade: III)
8. D.M. Green, J.A. Whitton, and M. Stovall Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study Am J Obstet Gynecol 187 2002 1070 1080 (Evidence Grade: II-2)
9. J.F. Winther, J.D. Boice Jr., A.L. Svendsen, K. Frederiksen, and J.H. Olsen Induced abortions in Danish cancer survivors: a population-based cohort study J Natl Cancer Inst 2009 (Evidence Grade: II-2)
10. M.J. Steiner, J. Trussell, and N. Mehta Communicating contraceptive effectiveness: a randomized controlled trial to inform a World Health Organization family planning book Am J Obstet Gynecol 195 2006 85 91 (Evidence Grade: I)
11. M.F. Mitwally Fertility preservation and minimizing reproductive damage in cancer survivors Expert Rev Anticancer Ther 7 2007 989 1001 (Evidence Grade: III)
12. D.C. Hodgson, M. Pintilie, and L. Gitterman Fertility among female Hodgkin's lymphoma survivors attempting pregnancy following ABVD chemotherapy Hematol Oncol 25 2007 11 15 (Evidence Grade: II-3)
13. A.H. Partridge, S. Gelber, and J. Peppercorn Fertility and menopausal outcomes in young breast cancer survivors Clin Breast Cancer 8 2008 65 69 (Evidence Grade: II-2)
14. J. Byrne, J.J. Mulvihill, and M.H. Myers Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer N Engl J Med 317 1987 1315 1321 (Evidence Grade: II-2)
15. M. Cvancarova, S.O. Samuelsen, H. Magelssen, and S.D. Fossa Reproduction rates after cancer treatment: experience from the Norwegian radium hospital J Clin Oncol 27 2009 334 343 (Evidence Grade: II-2)
16. Ethics Committee of the American Society for Reproductive Medicine Fertility preservation and reproduction in cancer patients Fertil Steril 83 2005 1622 1628 Epub 2005/06/14 (Evidence Grade: III)
17. M. Helewa, P. Levesque, D. Provencher, R.H. Lea, V. Rosolowich, and H.M. Shapiro Breast cancer, pregnancy, and breastfeeding J Obstet Gynaecol Can 24 2002 164 180 quiz 81-4 (Evidence Grade: II-2)
18. C. Sklar Maintenance of ovarian function and risk of premature menopause related to cancer treatment J Natl Cancer Inst Monogr 2005 25 27 (Evidence Grade: III)
19. Z. Blumenfeld, and M. von Wolff GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy Hum Reprod Update 14 2008 543 552 Epub 2008/10/01 (Evidence Grade: II-2)
20. S. Lie Fong, J.S. Laven, and F.G. Hakvoort-Cammel Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone Hum Reprod 24 2009 982 990 (Evidence Grade: II-2)
21. K. Lutchman Singh, M. Davies, and R. Chatterjee Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing Hum Reprod Update 11 2005 69 89 (Evidence Grade: III)
22. R.A. Anderson, A.P. Themmen, A. Al-Qahtani, N.P. Groome, and D.A. Cameron The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer Hum Reprod 21 2006 2583 2592 Epub 2006/07/06 (Evidence Grade: II-3)
23. W. Beguelin, M.C. Diaz Flaque, and C.J. Proietti Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3 Mol Cell Biol 30 2010 5456 5472 Epub 2010/09/30 (Evidence Grade: IV)
24. L. Holmberg, and H. Anderson HABITS steering and data monitoring committee. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455 Epub 2004/02/14 (Evidence Grade: I)
25. E. von Schoultz, and L.E. Rutqvist Stockholm Breast Cancer Study G. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial J Natl Cancer Inst 97 2005 533 535 Epub 2005/04/07 (Evidence Grade: I)
26. N.F. Col, J.A. Kim, and R.T. Chlebowski Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence Breast Cancer Res 7 2005 R535 R540 Epub 2005/07/01 (Evidence Grade: II-2)
27. C.A. Lange, and D. Yee Progesterone and breast cancer Womens Health (London, England) 4 2008 151 162 Epub 2008/12/17 (Evidence Grade: IV)
28. Y. Liang, I. Benakanakere, C. Besch-Williford, R.S. Hyder, M.R. Ellersieck, and S.M. Hyder Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice Menopause 17 2010 1040 1047 Epub 2010/05/13 (Evidence Grade: IV)
29. C. Lanari, and A.A. Molinolo Progesterone receptors - animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer Breast Cancer Res 4 2002 240 243 Epub 2002/12/11 (Evidence Grade: IV)
30. S.S. Chan, W.H. Tam, W. Yeo, M.M. Yu, D.P. Ng, and A.W. Wong A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women BJOG 114 2007 1510 1515 (Evidence Grade: I)
31. F.J. Gardner, J.C. Konje, K.R. Abrams, L.J. Brown, S. Khanna, and F. Al-Azzawi Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial Lancet 356 2000 1711 1717 (Evidence Grade: I)
32. M.D. Kesim, Y. Aydin, A. Atis, and G. Mandiraci Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen Climacteric 11 2008 252 257 (Evidence Grade: II-1)
33. X.B. Trinh, W.A. Tjalma, A.P. Makar, G. Buytaert, J. Weyler, and P.A. van Dam Use of the levonorgestrel-releasing intrauterine system in breast cancer patients Fertil Steril 90 2008 17 22 (Evidence Grade: II-2)
34. F.J. Gardner, J.C. Konje, and S.C. Bell Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system; long-term follow-up of a randomised control trial Gynecol Oncol 114 2009 452 456 Epub 2009/07/07. (Evidence Grade: I)
35. L. Beex, C. Rose, and H. Mouridsen Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC Phase III study (10863) Eur J Cancer 42 2006 3178 3185 Epub 2006/10/19 (Evidence Grade: I)
36. O. Kloke, U. Klaassen, and C. Oberhoff Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group Breast Cancer Res Treat 55 1999 51 59 (Evidence Grade: I)
37. S. Shapiro, L. Rosenberg, and M. Hoffman Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives Am J Epidemiol 151 2000 396 403 (Evidence Grade: II-2)
38. Post-marketing surveillance of Norplant((R)) contraceptive implants: II. Non-reproductive health(1) Contraception 63 2001 187 209 (Evidence Grade: II-2)
39. B.L. Strom, J.A. Berlin, and A.L. Weber Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer Contraception 69 2004 353 360 Epub 2004/04/24 (Evidence Grade: II-2)
40. T. Backman, I. Rauramo, and K. Jaakkola Use of the levonorgestrel- releasing intrauterine system and breast cancer Obstet Gynecol 106 2005 813 817 (Evidence Grade: II-2)
41. J. Dinger, K. Bardenheuer, and T.D. Minh Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer Contraception 83 2011 211 217 Epub 2011/02/12 (Evidence Grade: II-2)
42. J. McNaught, R.L. Reid, and D.M. Provencher Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada J Obstet Gynaecol Can 28 2006 616 639 (Evidence Grade: III)
43. World Health Organization Intrauterine devices in medical eligibility criteria for contraceptive use 4 ed. 2009 Reproductive Health and Research World Health Organization Geneva (Evidence Grade: III)
44. M. Di Nisio, N. Ferrante, and M. De Tursi Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy Thromb Haemost 104 2010 1049 1054 Epub 2010/09/02 (Evidence Grade: II-2)
45. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907 Epub 2008/01/25 (Evidence Grade: II-2)
46. M.P. Gomes, and S.R. Deitcher Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review Arch Intern Med 164 2004 1965 1976 Epub 2004/10/13 (Evidence Grade: II-2)
47. O. Lidegaard, B. Edstrom, and S. Kreiner Oral contraceptives and venous thromboembolism. A case-control study Contraception 57 1998 291 301 Epub 1998/07/23 (Evidence Grade: II-2)
48. H.T. Sorensen, L. Mellemkjaer, J.H. Olsen, and J.A. Baron Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 2000 1846 1850 Epub 2000/12/16 (Evidence Grade: II-2)
49. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 2006 458 464 Epub 2006/03/01 (Evidence Grade: II-2)
50. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost 5 2007 632 634 Epub 2007/02/27 (Evidence Grade: III)
51. Centers for Disease Control and Prevention U.S. medical eligibility criteria for contraceptive use, 2010 MMWR Early Release 59 2010 1 88 (Evidence Grade: III)
52. O. Lidegaard, E. Lokkegaard, A.L. Svendsen, and C. Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890 Epub 2009/08/15 (Evidence Grade: II-2)
53. A. Bergendal, V. Odlind, I. Persson, and H. Kieler Limited knowledge on progestogen-only contraception and risk of venous thromboembolism Acta Obstet Gynecol Scand 88 2009 261 266 Epub 2009/01/28 (Evidence Grade: II-2)
54. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study Contraception 57 1998 315 324 (Evidence Grade: II-2)
55. L.A. Heinemann, A. Assmann, T. DoMinh, and E. Garbe Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women Eur J Contracept Reprod Health Care 4 1999 67 73 Epub 1999/07/31 (Evidence Grade: II-2)
56. M.A. Lewis, L.A. Heinemann, K.D. MacRae, R. Bruppacher, and W.O. Spitzer The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women Contraception 54 1996 5 13 Epub 1996/07/01 (Evidence Grade: II-2)
57. O. Lidegaard, B. Edstrom, and S. Kreiner Oral contraceptives and venous thromboembolism: a five-year national case-control study Contraception 65 2002 187 196 (Evidence Grade: II-2)
58. N.R. Poulter, C.L. Chang, T.M. Farley, and O. Meirik Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications Lancet 354 1999 1610 (Evidence Grade: II-2)
59. C. Vasilakis, H. Jick, and M. del Mar Melero-Montes Risk of idiopathic venous thromboembolism in users of progestagens alone Lancet 354 1999 1610 1611 Epub 1999/11/24 (Evidence Grade: II-2)
60. M.K. Barsoum, J.A. Heit, A.A. Ashrani, C.L. Leibson, T.M. Petterson, and K.R. Bailey Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study Thromb Res 126 2010 373 378 Epub 2010/09/14 (Evidence Grade: II-2)
61. A. van Hylckama Vlieg, F.M. Helmerhorst, and F.R. Rosendaal The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device Arterioscler Thromb Vasc Biol 30 2010 2297 2300 Epub 2010/08/28 (Evidence Grade: II-2)
62. P. Darney, A. Patel, K. Rosen, L.S. Shapiro, and A.M. Kaunitz Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials Fertil Steril 91 2009 1646 1653 (Evidence Grade: II-1)
63. H. Ludwig, S. Van Belle, and P. Barrett-Lee The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients Eur J Cancer 40 2004 2293 2306 Epub 2004/09/30 (Evidence Grade: II-2)
64. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction Effects of contraceptives on hemoglobin and ferritin Contraception 58 1998 262 273 Epub 1999/01/12 (Evidence Grade: II-1)
65. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005:CD002126. Epub 2005/10/20 (Evidence Grade: I).
66. D. Hubacher, V. Reyes, and S. Lillo Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen Hum Reprod 21 2006 1467 1472 Epub 2006/02/18 (Evidence Grade: I)
67. B. Affandi An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon Contraception 58 6 Suppl 1998 99S 107S Epub 1999/03/30 (Evidence Grade: I)
68. D.M. Reid, J. Doughty, and R. Eastell Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group Cancer Treat Rev 34 Suppl. 1 2008 S3 S18 Epub 2008/06/03 (Evidence Grade: III)
69. B. Ramaswamy, and C.L. Shapiro Osteopenia and osteoporosis in women with breast cancer Semin Oncol 30 2003 763 775 Epub 2003/12/10 (Evidence Grade: III)
70. L. Gai, J. Zhang, H. Zhang, P. Gai, L. Zhou, and Y. Liu The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age Contraception 83 2011 218 222 Epub 2011/02/12 (Evidence Grade: II-1)
71. C. Meier, Y.B. Brauchli, S.S. Jick, M.E. Kraenzlin, and C.R. Meier Use of depot medroxyprogesterone acetate and fracture risk J Clin Endocrinol Metab 95 2010 4909 4916 Epub 2010/08/06 (Evidence Grade: II-2)
72. L.M. Lopez, D.A. Grimes, K.F. Schulz, and K.M. Curtis Steroidal contraceptives: effect on bone fractures in women Cochrane Database Syst Rev 95 2011 CD006033 PMID 21735401 (Evidence Grade: I)
73. P. Vestergaard, L. Rejnmark, and L. Mosekilde The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women Contraception 78 2008 459 464 Epub 2008/11/19 (Evidence Grade: II-2)
74. K.C. Watson, M.J. Lentz, and K.C. Cain Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities Womens Health Issues 16 2006 346 352 Epub 2006/12/26 (Evidence Grade: II-2)
75. S. Pongsatha, M. Ekmahachai, N. Suntornlimsiri, N. Morakote, and S. Chaovisitsaree Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years Int J Gynaecol Obstet 109 2010 223 225 Epub 2010/03/09 (Evidence Grade: II-3)
76. C. Monteiro-Dantas, X. Espejo-Arce, J.F. Lui-Filho, A.M. Fernandes, I. Monteiro, and L. Bahamondes A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants Reprod Health 4 2007 11 Epub 2007/11/14 (Evidence Grade: II-2)
77. L. Bahamondes, C. Monteiro-Dantas, and X. Espejo-Arce A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel- releasing contraceptive implants Hum Reprod 21 2006 466 470 (Evidence Grade: II-2)
78. M.V. Bahamondes, I. Monteiro, S. Castro, X. Espejo-Arce, and L. Bahamondes Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system Hum Reprod 25 2010 1158 1164 Epub 2010/02/27 (Evidence Grade: II-2)
79. A.K. Bhalla Management of osteoporosis in a pre-menopausal woman Best Pract Res Clin Rheumatol 24 2010 313 327 Epub 2010/06/11 (Evidence Grade: III)
80. L.A. Sim, L. McGovern, M.B. Elamin, B.A. Swiglo, P.J. Erwin, and V.M. Montori Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses Int J Eat Disord 43 2010 218 225 Epub 2009/04/08 (Evidence Grade: II-2)
81. C.S. Morrison, C. Sekadde-Kigondu, S.K. Sinei, D.H. Weiner, C. Kwok, and D. Kokonya Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 108 2001 784 790 Epub 2001/08/21 (Evidence Grade: II-2)
82. S.K. Sinei, C.S. Morrison, C. Sekadde-Kigondu, M. Allen, and D. Kokonya Complications of use of intrauterine devices among HIV-1-infected women Lancet 351 1998 1238 1241 Epub 1998/06/27 (Evidence Grade: II-2)
83. E.M. Stringer, C. Kaseba, and J. Levy A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus Am J Obstet Gynecol 197 2007 144.e1 144.e8 Epub 2007/08/11 (Evidence Grade: I)
84. K.M. Curtis, K. Nanda, and N. Kapp Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review AIDS 23 Suppl. 1 2009 S55 S67 Epub 2010/02/02 (Evidence Grade: II-2)
85. Y.F. Fong, and K. Singh Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient Contraception 60 1999 51 53 Epub 1999/11/05 (Evidence Grade: II-3)
86. M.E. Paulen, S.G. Folger, K.M. Curtis, and D.J. Jamieson Contraceptive use among solid organ transplant patients: a systematic review Contraception 82 2010 102 112 Epub 2010/08/05 (Evidence Grade: II-3)
87. J. Zerner, K.L. Doil, J. Drewry, and D.A. Leeber Intrauterine contraceptive device failures in renal transplant patients J Reprod Med 26 1981 99 102 Epub 1981/02/01 (Evidence Grade: II-3)
88. G. Sanna, K. Lorizzo, and N. Rotmensz Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors Ann Oncol 18 2007 288 292 Epub 2006/11/08 (Evidence Grade: II-2)
89. A.T. Meadows, D.L. Friedman, and J.P. Neglia Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort J Clin Oncol 27 2009 2356 2362 Epub 2009/03/04 (Evidence Grade: II-2)
90. P.C. Nathan, K.K. Ness, and M.C. Mahoney Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study Ann Intern Med 153 2010 442 451 Epub 2010/10/06 (Evidence Grade: II-2)
91. D.C. Hodgson, E.S. Koh, and T.H. Tran Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin's lymphoma Cancer 110 2007 2576 2586 Epub 2007/10/18 (Evidence Grade: II-3)
92. B.L. Xiao, L.Y. Zhou, X.L. Zhang, M.C. Jia, T. Luukkainen, and H. Allonen Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device Contraception 41 1990 353 362 Epub 1990/04/01 (Evidence Grade: II-3)
93. C.G. Nilsson, P.L. Lahteenmaki, T. Luukkainen, and D.N. Robertson Sustained intrauterine release of levonorgestrel over five years Fertil Steril 45 1986 805 807 Epub 1986/06/01 (Evidence Grade: II-3)
94. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies Lancet 347 1996 1713 1727 (Evidence Grade: II-2)
95. K.A. Rosenblatt, D.L. Gao, and R.M. Ray Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai Cancer Causes Control 20 2009 27 34 (Evidence Grade: II-2)
96. P.A. Marchbanks, J.A. McDonald, and H.G. Wilson Oral contraceptives and the risk of breast cancer N Engl J Med 346 2002 2025 2032 Epub 2002/06/28 (Evidence Grade: II-2)
97. M. Vessey, D. Yeates, and S. Flynn Factors affecting mortality in a large cohort study with special reference to oral contraceptive use Contraception 82 3 2010 221 229 Epub 2010/08/14 (Evidence Grade: II-2)
98. P.A. Wingo, H. Austin, P.A. Marchbanks, M.K. Whiteman, J. Hsia, and M.G. Mandel Oral contraceptives and the risk of death from breast cancer Obstet Gynecol 110 2007 793 800 (Evidence Grade: II-2)
99. Y. Lu, H. Ma, K.E. Malone, S.A. Norman, J. Sullivan-Halley, and B.L. Strom Oral contraceptive use and survival in women with invasive breast cancer Cancer Epidemiol Biomarkers Prev 20 2011 1391 1397 Epub 2011/05/10 (Evidence Grade: II-2)
100. M. Kumle, E. Weiderpass, and T. Braaten Norwegian-Swedish Women's Lifestyle and Health Cohort Study Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study Br J Cancer 90 2004 1386 1391 Epub 2004/04/01 (Evidence Grade: II-2)
101. Collaborative Group on Epidemiological Studies of Ovarian Cancer V. Beral, R. Doll, C. Hermon, R. Peto, and G. Reeves Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls Lancet 371 2008 303 314 Epub 2008/02/26 (Evidence Grade: II-2)
102. L. Dossus, N. Allen, and R. Kaaks Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition Int J Cancer 127 2 2010 442 451 Epub 2009/11/20 (Evidence Grade: II-2)
103. J.J. Kim, and E. Chapman-Davis Role of progesterone in endometrial cancer Semin Reprod Med 28 2010 81 90 Epub 2010/01/28 (Evidence Grade: III)
104. M.J. Buttini, S.J. Jordan, and P.M. Webb The effect of the levonorgestrel-releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review Aust N Z J Obstet Gynaecol 49 2009 316 322 Epub 2009/07/02 (Evidence Grade: II-3)
105. K.M. Curtis, P.A. Marchbanks, and H.B. Peterson Neoplasia with use of intrauterine devices Contraception 75 6 Suppl 2007 S60 S69 Epub 2007/05/29 (Evidence Grade: II-2)
106. R.B. Ness, R.C. Dodge, R.P. Edwards, J.A. Baker, and K.B. Moysich Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer Ann Epidemiol 21 2011 188 196 Epub 2010/11/27 (Evidence Grade: II-2)
107. S.S. Tworoger, K.M. Fairfield, G.A. Colditz, B.A. Rosner, and S.E. Hankinson Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk Am J Epidemiol 166 2007 894 901 Epub 2007/07/28 (Evidence Grade: II-2)
108. T. Dorjgochoo, and X.O. Shu Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006 Int J Cancer 124 2009 2442 2449 Epub 2009/01/27 (Evidence Grade: II-2)
109. L.B. Zapata, M.K. Whiteman, P.A. Marchbanks, and K.M. Curtis Intrauterine device use among women with ovarian cancer: a systematic review Contraception 82 2010 38 40 Epub 2010/08/05 (Evidence Grade: II-2)
110. S. Iodice, M. Barile, and N. Rotmensz Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis Eur J Cancer 46 2010 2275 2284 Epub 2010/06/12 (Evidence Grade: II-2)
111. A. Gadducci, N. Biglia, S. Cosio, P. Sismondi, and A.R. Genazzani Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy Gynecol Endocrinol 26 2010 568 577 Epub 2010/07/17 (Evidence Grade: III)